tions for pulmonary function laboratory directors, which re- quire that the pulmonary function technician be certified by the National Board of Respiratory Care or ...
ARTHRITIS & RHEUMATISM Vol. 58, No. 6, June 2008, pp 1810–1822 DOI 10.1002/art.23501 © 2008, American College of Rheumatology
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Oral Type I Collagen Treatment in Patients With Diffuse Cutaneous Systemic Sclerosis I. Oral Type I Collagen Does Not Improve Skin in All Patients, but May Improve Skin in Late-Phase Disease Arnold E. Postlethwaite,1 Weng Kee Wong,2 Philip Clements,2 Soumya Chatterjee,3 Barri J. Fessler,4 Andrew H. Kang,1 Joseph Korn,† Maureen Mayes,6 Peter A. Merkel,5 Jerry A. Molitor,7 Larry Moreland,4 Naomi Rothfield,8 Robert W. Simms,2 Edwin A. Smith,9 Robert Spiera,10 Virginia Steen,11 Kenneth Warrington,1 Barbara White,12 Frederick Wigley,13 and Daniel E. Furst2 Objective. To investigate the safety and efficacy of oral bovine type I collagen (CI) treatment in patients who have had diffuse cutaneous systemic sclerosis (dcSSc; scleroderma) for
